Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Mol Cancer Ther. 2021 Sep 4;20(11):2189–2197. doi: 10.1158/1535-7163.MCT-21-0126

Figure 2: Repotrectinib Anti-Proliferative Activity in Neuroblastoma Cell Lines as Monotherapy and in Combination with Chemotherapy.

Figure 2:

(A) Repotrectinib cytotoxicity (IC50) in neuroblastoma cell lines tested stratified by ALK status, MYCN status, and TP53 status; Combination index (CI) of IRI/TMZ/REPO (blue) or IRI/TMZ/ENS (green) in ALK WT (B) or ALK aberrant (C) neuroblastoma cell lines; solid line: median fractional effect; shaded regions: 1.96 x standard error; IRN=irinotecan; TMZ=temozolomide; REPO=repotrectinib, ENS=ensartinib